Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene Ciloleucel and Radiotherapy in Relapsed/Refractory Follicular Lymphoma
NCT06043323Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2024
- Primary completion
- Sep 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in follicular lymphoma (FL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of grade 3 or higher cytokine release syndrome (CRS) at 30 days and Incidence of Adverse Events at 1 year. Started Jan 2024; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06043323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06043323.